Warning letter · FDA Warning Letters, Historical Archive

MusclMasster, LLC: FDA Warning Letter (Aug 30, 2017)

Agency action: Aug 30, 2017Record ID: fda_warning_-1a5dc92f60c61f69
View official source ↗

What happened

Original notice title

MusclMasster, LLC 8/30/17

From the archived source record

Based on the inspection, a review of the product labels collected during the inspection, and a review of your website at www.thegreenherb.com, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. The use of ephedrine alkaloids in your dietary supplement product AL-ER-G causes the product to be adulterated within the meaning of section 402(f)(1)(A)(ii) of the Act [21 U.S.C. § 342(f)(1)(A)(ii)] in that it is a dietary supplement that contains a dietary ingredient that presents a significant or unreasonable risk of illness or injury under ordinary conditions of use (see also 21 Code of Federal Regulations (CFR) 119.1). We acknowledge that you stated that you voluntarily destroyed all Ephedra-containing ingredients and dietary supplement products in your possession during the inspection and that you issued a voluntary nationwide recall for the product AL-ER-G. Unapproved New Drugs/Misbranded Drugs FDA reviewed your website at www.thegreenherb.com in July 2017 and has determined that you take orders there for the products Vas-Q-Lar, Vir-L IV, and Nu Woman. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, Vas-Q-Lar and Vir-L IV fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)]. Dietary Supplement CGMP Violations The dietary supplement products that you manufacture, package, label, and/or hold are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because the products have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulations for dietary supplements, 21 CFR Part 111.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
0cec46ea1a91

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
AL-ER-G; About Us; Pau D’arco Bark – potential anti-fungal, anti-tumor & anti-canceral properties; [I]ssues associated with: Viral Infections; Supplement Facts; (b)(4) capsules provide; Eleuthero; Nu-Woman; Nu Man Plus; Vir-L IV; and Vir-L IV products as dietary supplements; Vas-Q-Lar; and Nu Woman; strokes” Vir-L IV “[I]ssues associated with: Viral Infections” Your products; but the capsule ingredients; label suggests consumers take (b)(4) capsules (b)(4)
Company
MusclMasster, LLC
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.